Acetylcholine receptor-β inhibition by interleukin-6 in skeletal muscles contributes to modulating neuromuscular junction during aging
Open Access
- 10 October 2024
- journal article
- research article
- Published by Springer Nature in Molecular Medicine
- Vol. 30 (1) , 1-15
Abstract
Background: Aging-related strength decline contributes to physiological deterioration and is a good predictor of poor prognosis. However, the mechanisms underlying neuromuscular junction disorders affecting contraction in aging are not well described. We hypothesized that the autocrine effect of interleukin (IL)-6 secreted by skeletal muscle inhibits acetylcholine receptor (AChR) expression, potentially causing aging-related strength decline. Therefore, we investigated IL-6 and AChR β-subunit (AChR-β) expression in the muscles and sera of aging C57BL/6J mice and verified the effect of IL-6 on AChR-β expression. Methods: Animal experiments, in vitro studies, bioinformatics, gene manipulation, dual luciferase reporter gene assays, and chromatin immunoprecipitation experiments were used to explore the role of the transcription cofactor peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC1α) and its interacting transcription factors in the IL-6-mediated regulation of AChR-β expression. Results: IL-6 expression gradually increased during aging, inhibiting AChR-β expression, which was reversed by tocilizumab. Both tocilizumab and the PGC1α agonist reversed the inhibiting effect of IL-6 expression on AChR-β. Compared to inhibition of signal transducer and activator of transcription 3, extracellular signal-regulated kinases 1/2 (ERK1/2) inhibition suppressed the effects of IL-6 on AChR-β and PGC1α. In aging mouse muscles and myotubes, myocyte enhancer factor 2 C (MEF2C) was recruited by PGC1α, which directly binds to the AChR-β promoter to regulate its expression. Conclusions: This study verifies AChR-β regulation by the IL-6/IL-6R-ERK1/2-PGC1α/MEF2C pathway. Hence, evaluating muscle secretion, myokines, and AChRs at an earlier stage to determine pathological progression is important. Moreover, developing intervention strategies for monitoring, maintaining, and improving muscle structure and function is necessary.Keywords
Funding Information
- the Foundation of Shanghai Municipal Commission of Health and Family Planning (202342134)
- the National Science Foundation of China (82171254)
- the Science, Technology, and Innovation Action Plan for Sustainable Development in the Chongming District of Shanghai (CKY2420-27, CKY2420-27)
This publication has 61 references indexed in Scilit:
- Interleukin‐6 initiates muscle‐ and adipose tissue wasting in a novel C57BL/6 model of cancer‐associated cachexiaJournal of Cachexia, Sarcopenia and Muscle, 2022
- A neuromuscular perspective of sarcopenia pathogenesis: deciphering the signaling pathways involvedGeroScience, 2022
- Mouse models of sarcopenia: classification and evaluationJournal of Cachexia, Sarcopenia and Muscle, 2021
- Motoneuron deafferentation and gliosis occur in association with neuromuscular regressive changes during ageing in miceJournal of Cachexia, Sarcopenia and Muscle, 2020
- Utility and Safety of Tocilizumab in Takayasu Arteritis with Severe Heart Failure and Muscle WastingESC Heart Failure, 2019
- Cortisol Induces Reactive Oxygen Species Through a Membrane Glucocorticoid Receptor in Rainbow Trout MyotubesJournal of Cellular Biochemistry, 2016
- Sarcopenia: describing rather than defining a conditionJournal of Cachexia, Sarcopenia and Muscle, 2014
- Regulation of muscle acetylcholine receptor turnover by β subunit tyrosine phosphorylationDevelopmental Neurobiology, 2013
- Molecular control of neuromuscular junction developmentJournal of Cachexia, Sarcopenia and Muscle, 2011
- Inflammatory Markers and Loss of Muscle Mass (Sarcopenia) and StrengthThe American Journal of Medicine, 2006